1. Seeman T., Gilík J., Vondrák K. et al. Regression of left-ventricle hypertrophy in children and adolescents with hypertension during ramipril monotherapy. Am J Hypertens 2007;20(9):990-6.
2. Lonn E.M., Yusuf S., Jha P. et al. Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection. Circulation 1994;90(4):2056-69.
3. Yusuf S., Pepine C.J., Garces C. et al. Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions. Lancet 1992;340(8829):1173-8.
4. Pfeffer M.A., Braunwald E., Моуё L.A. et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the Survival and Ventricular Enlargement trial. N Engl J Med 1992;327(10):669-77.
5. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-convertingenzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342(3):145-53.
6. Tu К., Mamdani M.M., Jacka R.M. et al. The striking effect of the Heart Outcomes Prevention Evaluation (HOPE) on ramipril prescribing in Ontario. CMAJ 2003;168(5):553-7.
7. Pilote L., Abrahamowicz M., Rodrigues E. et al. Mortality Rates in Elderly Patients Who Take Different Angiotensin-Converting Enzyme Inhibitors after Acute Myocardial Infarction: A Class Effect? Ann Intern Med 2004;141(2):102- 12.
8. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. AIRE Study Investigators. Lancet 1993; 342(8875):821-8.
9. Hall A.S., Murray G.D., Ball S.G. Follow-up study of patients randomly allocated ramipril or placebo for heart failure after acute myocardial infarction: AIRE Extension (AIREX) Study. Lancet 1997;349(9064):1493-97.
10. Pfeffer M.A., Greaves S.C., Arnold J.M. et al. Early versus delayed angiotensinconverting enzyme inhibition therapy in acute myocardial infarction. The healing and early afterload reducing therapy trial. Circulation 1997;95(12):2643-51.
11. Beluzzi F., Sernesi L., Preti P. et al. Prevention of recurrent lone atrial fibrillation by the angiotensin-II converting enzyme inhibitor ramipril in normotensive patients. J Am Coll Cardiol 2009;53(1):24-9.
12. Mogensen C.E. Long-term antihypertensive treatment inhibiting progression of diabetic nephropathy. Br Med J (Clin Res Ed). J 1982;285(6343):685- 89.
13. Parving H.H., Andersen A.R., Smidt U.M., Swendsen P.A. Early aggressive antihypertensive treatment reduces rate of decline in kidney function in diabetic nephropathy. Lancet 1983;1(8335):1175-9.
14. Björck S., Mulec H., Johnsen S.A. et al. Renal protective effect of enalapril in diabetic nephropathy. BMJ 1992;304(6823):339-43.
15. Parving H.H., Hommel E., Smidt U.M. Protection of kidney function and decrease in albuminuria by captopril in insulin dependent diabetics with nephropathy. BMJ 1988;297(6656):1086-91.
16. Lewis E.J., Hunsicker L.G., Bain R.P., Rohde E.D. The effect of angiotensinconverting enzyme inhibition on diabetic nephropathy. N Engl J Med 1993;329(20):1456-62.
17. Kasiske B.L., Kalil R.S., Ma J.Z. et al. Effects of antihypertensive therapy on the kidney in patients with diabetes: a meta-regression analysis. Ann Intern Med 1993;118(2):129-38.
18. Weidmann P., Schneider M., Böhlen L. Therapeutic efficacy of different antihypertensive drugs inhuman diabetic nephropathy: an updated meta-analysis. Nephrol Dial Transplant 1995;10(Suppl 9):39-45.
19. O'Hare P., Bilbous R., Mitchell T. et al. Low-dose ramipril reduces microalbuminuria in type 1 diabetic patients without hypertension. The ATLANTIS study group. Diabetes Care 2000;23(12):1823-9.
20. Marre M., Lievre M., Chatellier G. et al. Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: randomised, double blind, placebo controlled trial (the DIABHYCAR study). BMJ 2004;328(7438):495.
21. Ruggenenti P., Perna A., Gherardi G. et al. Renoprotective properties of ACEinhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet 1999;354(9175):359-64.
22. Ruggenenti P., Perna A., Gherardi G. et al. Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Lancet 1998;352(9136):1252-6.
